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ttp://dx.doi.org/10.1016/j.jmoldx.2015.11.005Newborn screening for cystic ﬁbrosis enables early detection and management of this debilitating
genetic disease. Implementing comprehensive CFTR analysis using Sanger sequencing as a component
of conﬁrmatory testing of all screen-positive newborns has remained impractical due to relatively
lengthy turnaround times and high cost. Here, we describe CFseq, a highly sensitive, speciﬁc, rapid
(<3 days), and cost-effective assay for comprehensive CFTR gene analysis from dried blood spots, the
common newborn screening specimen. The unique design of CFseq integrates optimized dried blood
spot sample processing, a novel multiplex ampliﬁcation method from as little as 1 ng of genomic
DNA, and multiplex next-generation sequencing of 96 samples in a single run to detect all relevant
CFTR mutation types. Sequence data analysis utilizes publicly available software supplemented by an
expert-curated compendium of >2000 CFTR variants. Validation studies across 190 dried blood spots
demonstrated 100% sensitivity and a positive predictive value of 100% for single-nucleotide variants
and insertions and deletions and complete concordance across the polymorphic poly-TG and
consecutive poly-T tracts. Additionally, we accurately detected both a known exon 2,3 deletion and a
previously undetected exon 22,23 deletion. CFseq is thus able to replace all existing CFTR molecular
assays with a single robust, deﬁnitive assay at signiﬁcant cost and time savings and could be adapted
to high-throughput screening of other inherited conditions. (J Mol Diagn 2016, 18: 267e282;
http://dx.doi.org/10.1016/j.jmoldx.2015.11.005)Supported by NIH grants R01HD081355 (C.S.) and P30CA016672
(W.W.) and CPRIT grant RP100030 (W.W.).
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Current address of C.S., Department of Genetics, Yale School of Med-
icine, New Haven, CT.With an overall incidence of 1 in approximately 3900
population in the United States, cystic ﬁbrosis (CF; Online
Mendelian Inheritance in Man no. 219700, http://www.ncbi.
nlm.nih.gov/omim) is among the most common genetic
disorders.1,2 CF is an autosomal recessive disease caused by
mutations in the CF transmembrane conductance regulator
gene (CFTR). Whereas a single variant, the deletion of
Phe508 (c.1521_1523delCTT, p.Phe508del), accounts for
approximately 70% of CF chromosomes worldwide,3 nearly
2000 other single-nucleotide variants (SNVs), insertions and
deletions (indels), and genomic copy number variationstigative Pathology and the Association for Mole
rg/licenses/by-nc-nd/4.0).(CNVs) have been identiﬁed (Cystic Fibrosis Genetic
Analysis Consortium, http://www.genet.sickkids.on.ca;
CFTR2 database, http://www.cftr2.org, last accessedcular Pathology. Published by Elsevier Inc. This is an open access article under the CC
Lefterova et alOctober 21, 2015). Moreover, these variants have diverse
functional consequences and varying prevalences across
ethnicities,1,3,4 emphasizing the need for comprehensive
and deﬁnitive CFTR analysis in CF molecular testing.
Due to its high prevalence, devastating clinical
sequelae, and responsiveness to early intervention, uni-
versal newborn screening (NBS) for CF has been imple-
mented across the United States and in many countries
worldwide, with substantial clinical effect. Indeed, NBS
has been shown to accelerate the identiﬁcation of children
at risk for CF by approximately 1 year compared with
symptomatic presentation.5 This early identiﬁcation allows for
early initiation of nutritional support, respiratory therapy, and
prophylaxis against infectious complications, all of which have
long-term beneﬁts, including improved growth, reduced
hospitalizations, and extended survival.5,6
Although effective in identifying at-risk children, current
CF NBS strategies vary widely.7 Most begin with immu-
noreactive trypsinogen testing of dried blood spots (DBSs)
taken from newborn heel sticks. This assay is sensitive but
has a marked lack of speciﬁcity. Indeed, the false-positive
rate of immunoreactive trypsinogen testing is approxi-
mately 94%,8 generating a large number of newborns who
require follow-up testing.7 To accommodate this lack of
speciﬁcity, NBS programs rely on tiered screening strate-
gies, which reﬂex hypertrypsinogenemic specimens to
methods that interrogate a relatively small number of com-
mon mutations. These panels, however, have limited
sensitivity, especially in nonwhite ethnic groups.1,8 In Cal-
ifornia’s diverse population, novel CFTR variations are
being found in newborns at rates of 18 per year, in which
10% to 20% appear CF causing.8 Asymptomatic infants
with one CF-causing mutation and a second mutation of
variable clinical consequence and who have sweat chloride
levels below the diagnostic range for CF in the ﬁrst months
of life are increasingly being reported to have CF as they
age,9,10 leaving NBS programs with limited CFTR testing
misclassifying these infants as carriers.
These data support the need for comprehensive CFTR
analysis as a component of CF NBS. Until recently, such
comprehensive CFTR testing was performed exclusively
through Sanger sequencing, which is costly, laborious, and
time consuming and, therefore, impractical as a second-tier
test for most NBS programs. The relatively recent advent of
next-generation sequencing (NGS) technologies presents a
solution to these limitations. Indeed, these approaches have
the potential to provide clinical-grade sequence analysis of
the entire CFTR gene at less cost than the currently used
screening methods.11 Several studies have recently reported
the development of NGS assays for CF testing,11,12 one of
which has been cleared by the US Food and Drug Admin-
istration.13 Despite this initial work, these assays remain
limited in both cost-effectiveness and sample requirements.
For example, current NGS assays often require relatively
large quantities of high-quality genomic DNA derived from
fresh peripheral blood samples, which requires an additional268appointment and blood draw. Current screening programs,
however, generally collect only DBSs from newborns and
rely on 3.2-mm punches, which yield low quantities of
DNA at variable quality,14 limiting currently used down-
stream NGS applications. To date, only a single NGS CF
screening assay has been able to provide accurate results
using a single 3.2-mm DBS punch; however, that assay is
limited to approximately 170 pathogenic sequence variants,
which, while an advance over currently used panel-based
screening techniques, does not represent truly comprehen-
sive CFTR testing.15 Additionally, existing NGS CF assays
have reported multiplexing capabilities of 8 to 48 specimens
per run,11e13,15 which may be insufﬁcient throughput for
large screening programs that handle thousands of speci-
mens per year and may lead to an unnecessarily high cost
per specimen.
Here we describe the design, development, and vali-
dation of CFseq, a highly sensitive, speciﬁc, cost-
effective, and rapid clinical NGS assay that reliably
sequences all exons, ﬂanking intronic regions, and key
noncoding regions of the CFTR gene from a single
3.2-mm newborn DBS punch. This performance is ach-
ieved through optimized DBS sample processing and
DNA extraction, a novel multiplex PCR (mPCR)-based
target ampliﬁcation strategy, and standard NGS using the
MiSeq platform (Illumina, San Diego, CA) coupled with
a customizable automated bioinformatics pipeline for data
analysis and interpretation. Importantly, the CFseq design
allows for 96 samples to be pooled and run simultaneously,
reducing the per-sample reagent cost to as little as one-ﬁfth
that of traditional tiered NBS testing and the turnaround
time to as little as 3 days. With these performance parame-
ters, this single workﬂow may be able to completely replace
existing algorithms for CF NBS and provide comprehensive
analysis for all hypertrypsinogenemic infants, while reducing
cost and turnaround time and providing superior molecular
diagnosis.
Materials and Methods
Study Specimens
A total of 193 de-identiﬁed residual DBS specimens from
California NBSwere used for validating the performance of the
assay. Two separate samples were selected to include a large
variety of CFTR variant types: 111 unique known SNVs and
indels, including both benign and pathogenic variants, and one
known CNV (deletion of exons 2 and 3). The ﬁrst sample was
composed of 142 residual newbornDBS specimens undergoing
Sanger sequencing at the Stanford Health Care Molecular
Pathology Laboratory (Stanford, CA) between April 2013 and
May 2014. The second sample included 51 archived specimens
with known CF variants from the promoter region and all in-
trons and exons, except introns 23 and 25 and exon 10. Residual
DBS specimens were stored at 4C or 20C before testing.
This study was exempt from written informed consent becausejmd.amjpathol.org - The Journal of Molecular Diagnostics
Cystic Fibrosis NGS in Newbornsthe samples constituted nonidentiﬁable, residual clinical speci-
mens used for clinical assay validation.
DNA Extraction
For each DBS, a 3.2-mm punch was obtained using a PE
Wallac instrument (Perkin Elmer, Waltham, MA) and
deposited into a 96-well plate. For consistency, the punch
was made in the center of one blood spot on a ﬁve-spot NBS
blood card. Three blank spots were punched between samples
to prevent cross-contamination. DBS punch spots were
washed twice with 180 mL of 10 mmol/L NaOH. Each punch
spot was then suspended in 50 mL of 10 mmol/L NaOH
solution and heated at 99C for 15 minutes in an Applied
Biosystems GeneAmp PCR System 9700 (Life Technologies,
Grand Island, NY). The supernatant, containing eluted DNA,
was mixed by pipetting and then transferred to a clean tube
containing 50 mL of 20 mmol/L TrisCl pH 7.5.
Comparison of DNA Extraction Methods
We prepared simulated blood cards using standard NBS ﬁlter
paper (provided by the California Department of Public
Health) and 75 mL of residual whole blood in EDTA, so that
multiple spots could be punched and used for parallel testing
of different extraction methods. Speciﬁcally, we performed
extractions using the crude sodium hydroxideebased method
described under DNA Extraction, and two commercial re-
agents: the QIAamp DNA Micro Kit (Qiagen, Redwood City,
CA), and the Generation Capture Column Kit without use of
the presupplied columns (Gentra Systems, Minneapolis, MN).
Extractions were performed according to the manufacturers’
protocols. We tested eluates obtained directly from these
methods and also after concentration, with an Amicon Ultra
30K ﬁlter (EMD Millipore, Billerica, MA). DNA yield was
assessed using the Qubit HS assay (Life Technologies). We
further tested the performance of the assay using one or two
punch spots for extraction. We performed multiplex target
capture, library preparation, and sequencing for eluates from
all extraction in comparison.
Primer Design
We used a custom Perl scripteintegrating primer design
code from Primer 316 to generate target-speciﬁc forward and
reverse primers (Table 1) for 43 amplicons covering 16,513
bp of the CFTR region of interest (ROI), based on the hg19/
GRCh37 human reference genome. The ROI was deﬁned as
all exons and 20 bp of ﬂanking intronic sequence and
selected portions of the 50-untranslated region and introns 12
and 22 (legacy names, IVS11 and IVS19, respectively)
known to contain pathogenic variants (Supplemental Table
S1). Primer hybridization sites were selected to avoid
common polymorphisms found in the National Center for
Biotechnology Information’s Single-Nucleotide Poly-
morphism Database (dbSNP) build 137, June 2012 release.The Journal of Molecular Diagnostics - jmd.amjpathol.orgPrimers were designed to have similar length (mean, 23 bp;
range, 21 to 27 bp), GC-content, and amplicon size (mean,
384 bp; range, 350 to 407 bp), matching the 2  250-bp
paired-end sequencing chemistry of the MiSeq platform
(Illumina). Exons larger than 350 bp were covered by
overlapping amplicons. Adapter sequences (24 bp) were
included at the 50 end of each primer for postcapture
ampliﬁcation and sequence library construction.
Multiplex CFTR Target Capture
The 43 primer pairs were pooled together in a single tube for
multiplex CFTR target capture. The 193 samples were tested
on three runs: multiplexing 47, 95, or 51 samples per run; a
no-template water control was also included on the ﬁrst two
runs. mPCR was performed in a Veriti 96-well thermal cycler
(Applied Biosystems, Foster City, CA) using 4 mL of extracted
DNA in a 20-mL ﬁnal volume and the KAPA2G Fast Multi-
plex PCR Kit (Kapa Biosystems, Wilmington, MA) across the
following thermal proﬁle: 95C for 3 minutes, 60C for 3
minutes, 5 cycles at 95C for 16 seconds and 60C for 1
minute, 10 cycles at 95C for 16 seconds and 72C for 15
seconds, and 72C for 2 minutes. After mPCR, each sample
was treated with 8 units of exonuclease I (New England
BioLabs, Ipswich, MA) at 37C for 45 minutes, 80C for 20
minutes, and 95C for 5 minutes.
Sequence Library Construction and Sequencing
Sequencing library preparation for the MiSeq platform was
performed according to the manufacturer’s instructions
using 4 mL of mPCR product (ie, captured DNA) per
sample. PCR was set up in 20 mLevolume reactions, using
common primers with sample-speciﬁc indices and Illumi-
na’s P5 and P7 adapter sequences attached at the 50 end.
Samples were barcoded with a single 6-bp index (up to 48
samples) or 8-bp dual indices (up to 96 samples) according
to Illumina’s index-sequencing protocol. The KAPA2G
Fast Multiplex PCR Kit (Kapa Biosystems) was used for
amplifying captured DNA samples with the following
cycling conditions: 98C for 50 seconds, 14 cycles at 98C
for 16 seconds and 72C for 20 seconds, and a ﬁnal
extension at 72C for 2 minutes. Four microliters of each
sample was then pooled and puriﬁed using AMPure XP
(Beckman Coulter, Brea, CA) using a bead/sample ratio of
0.7:1 and eluted in 30 mL (48 samples) or 60 mL (96 sam-
ples) in 10 mmol/L Tris-Cl buffer (pH 8.5). DNA concen-
tration was measured by a 2100 Bioanalyzer instrument
(Agilent Technologies, Santa Clara, CA) and sequenced on
the MiSeq instrument using a 2  250-bp paired-end kit
according to the manufacturer’s protocol.
Sequencing Data Analysis
Image analysis and sample demultiplexing were performed
with MiSeq Control Software version 2.4.1 and MiSeq269
Table 1 CFseq Primers
ID Forward primer sequence Reverse primer sequence
CFTR_promotor 50-TGCTTGGCTTCCTTTCGGTGGAT-30 50-CGGCAGTGTGGGTCTGATGCATT-30
CFTR_utr5_1 50-TGGGCCGGTAATTACGCAAAGCA-30 50-CTTCCTAGACCCTCCTTCGCGTC-30
CFTR_utr5_2 50-CGGAACTTTTCGGCTCTCTAAGGC-30 50-CGCACCTCCCTTTCCCGATTCTG-30
CFTR_rs139688774 50-CCTAAAGAGAGGCCGCGACTGTC-30 50-ACCTACTACTCTGGGTGCCTGCC-30
CFTR_exon_1 50-GTGGGTGGAGAAAGCCGCTAGAG-30 50-CAACCCATACACACGCCCTCCTC-30
CFTR_exon_2n1* 50-GTGACAGTCACATTAGTTCAGAGAT-30 50-ACTTATAATATGTTTGCTTTCTCTTCTC-30
CFTR_exon_3* 50-AGGACAACTAAAATATTTGCACATGC-30 50-AAATTGCCACCCGTGTTCCAGGA-30
CFTR_exon_4* 50-AGTCTTGTGTTGAAATTCTCAGGGT-30 50-TCCCTTACTTGTACCAGCTCACT-30
CFTR_exon_5* 50-TCTGCCTAGATGCTGGGAAATAA-30 50-CCCAGGAAAACTCCGCCTTTCCA-30
CFTR_exon_6n 50-TTAGTGTGCTCAGAACCACGAAG-30 50-TGACACTGAAGATCACTGTTCTATGCA-30
CFTR_exon_7 50-GGTGGAAGTCTACCATGATAAACA-30 50-GCGTCTGGCACATAGGAGGCATT-30
CFTR_exon_8 50-CATTAGAACTGATCTATTGACTGA-30 50-ACCATGCTCAGATCTTCCATTCCA-30
CFTR_exon_9 50-AAGATGTAGCACAATGAGAGTAT-30 50-ACAACCATGAGCACCTGGCCATT-30
CFTR_exon_10 50-TGGATCATGGGCCATGTGCTTTT-30 50-TCTCCAAAAATACCTTCCAGCACT-30
CFTR_exon_11n 50-TATACACTTCTGCTTAGGATGATAATTG-30 50-GGAAACATAAATATATGTAGACTAACCG-30
CFTR_processed_transcript_3 50-GCCCCGATCACCAAATGCAAACA-30 50-ACCTGACTTCTCACTCATGGCTGT-30
CFTR_exon_12n 50-TGTGCCTTTCAAATTCAGATTGAGCA-30 50-AGGCAAACAAATACACTGACACCAAG-30
CFTR_intron_12* 50-ACAGAGTGTGGGGAAGAAACTGTGT-30 50-TGAAACCATAAGCAAGTAAAATCTACA-30
CFTR_exon_13y 50-TGCATGTAGTGAACTGTTTAAGGCA-30 50-AGCATGAGGCGGTGAGAAAAGGT-30
CFTR_exon_14_3a 50-ACAAAATGCTAAAATACGAGACA-30 50-GTCCAGGAGACAGGAGCATCTCC-30
CFTR_exon_14_3b 50-TCATGGGATGTGATTCTTTCGACCA-30 50-TCAGGACAGACTGCCTCCTTCGT-30
CFTR_exon_14_3c 50-ACTCAATTGCATTCTGTGGGGTGA-30 50-AGCCTTTAGAGAGAAGGCTGTCCT-30
CFTR_exon_15 50-AAGCTGTGTTGCTCCAGTAGACA-30 50-TGTATACATCCCCAAACTATCTT-30
CFTR_exon_16y 50-TGTGGGCATGGGAGGAATAGGTG-30 50-GGAGTGCGGTGGCTACTCACAAT-30
CFTR_exon_17 50-TCAGTAAGTAACTTTGGCTGCCA-30 50-ACCACAGGCCCTATTGATGGTGG-30
CFTR_exon_18n 50-GCTAATTCTTATTTGGGTTCTGAATGC-30 50-CAGGTTTGGGCCAGGTAAGCAGT-30
CFTR_exon_19n 50-ACACACTTTGTCCACTTTGCAATGT-30 50-AGTTTCCTTTTATATACACATGCATGT-30
CFTR_exon_20_2a1 50-AGTTCCCATCTCTGGTAGCCAAGT-30 50-GTTGACAGGTACAAGAACCAGTTGG-30
CFTR_exon_20_2b1 50-TCCGATTTCAAGGAAATTATTTGT-30 50-GGACGGCAGCCTTACTTTGAAAC-30
CFTR_exon_21 50-AAGTCGTTCACAGAAGAGAGAAA-30 50-ACAGGTGAAAGAATGCTCACTGC-30
CFTR_exon_22_2a 50-AGCCCGACAAATAACCAAGTGACA-30 50-AATCTCACCCTCTGGCCAGGACT-30
CFTR_exon_22_2b 50-TGGCTTCTTTAGTTATTAACCTAGCA-30 50-CCTCAGGGGGCCAAATGACTGTC-30
CFTR_intron_target_27b 50-AGTAGTTGAATCATTCAGTGGGT-30 50-ACTTCAATGCACCTCCTCCCTGA-30
CFTR_exon_23 50-TGAGTACAAGTATCAAATAGCAGT-30 50-TGGTCAGGATTGAAAGTGTGCAACA-30
CFTR_exon_24 50-CCTGTTGCTCCAGGTATGTTAGGGT-30 50-ACTTGATGGTAAGTACATGGGTGT-30
CFTR_exon_25* 50-ATGTGTCACCATGAAGCAGGCAT-30 50-GCAGGTAGTGGGGGTAGAGGGAT-30
CFTR_exon_26* 50-TGCAGGAACTATCACATGTGAGA-30 50-CCCCATGGTTGAAAAGCTGATTGTGG-30
CFTR_exon_27_6a 50-TGTGCCAGTTTCTGTCCCTGCTC-30 50-AGGCAGAGGTAACTGTTCCACGA-30
CFTR_exon_27_6c 50-GAAACTCGTTAATTTGTAGTGTTG-30 50-ACCATCCTGTCCCCTGTGAAAGA-30
CFTR_exon_27_6b 50-ACCGCTGAAGTTTCCAGTTATCA-30 50-TCGTGGGACAGTCACCTCATGGA
CFTR_exon_27_6e1 50-CCATGGGCACTGTGGGTAGACAC-30 50-TAGGTTCTCCCCTGTCCCAGTT-30
CFTR_exon_27_6d1 50-ACATCTAGCCTGAAAACATACCA-30 50-TCCAGATCCTGGAAATCAGGGTT-30
CFTR_exon_27_6f 50-TGAAATATTGACTTTTTATGGCACT-30 50-TGGAGTGAGAGACTGATGAAACA-30
(table continues)
*These primers were also used for real-time quantitative PCR (qPCR) veriﬁcation of the predicted CNVs in exon 2, 3, 4, 5, 25, and 26, and
intron 12.
yThese primers were used in qPCR veriﬁcation to target reference exons 13 and 16, which were used for normalize the ampliﬁcation signal
at the exons of interest.
F, forward; R, reverse.
Lefterova et alReporter version 2.5.1.3 (Illumina). Primer sequences were
identiﬁed in reads using cross_match version 0.990329
(compiled with the “manyreads” option; http://www.phrap.
org). Primers in regions where amplicons overlap were
trimmed from read ends using Biopython17 in a customized
Python script (available at https://github.com/eulaf/CFseq).270The resulting processed fastq ﬁles were aligned to the
hg19/GRCh37 human reference genome using Burrows-
Wheeler AlignereMEM version 0.7.12-r1039.18 Picard19
was used for sorting and converting ﬁles to BAM format.
Customized Python scripts (available at https://github.com/
eulaf/CFseq) using the pysam module were used forjmd.amjpathol.org - The Journal of Molecular Diagnostics
Length Strand Forward primer start Forward primer end Reverse primer start Reverse primer end Forward length Reverse length
364 F 117119062 117119084 117119403 117119425 22 22
400 F 117119232 117119254 117119609 117119631 22 22
397 F 117119426 117119449 117119800 117119822 23 22
394 F 117119694 117119716 117120065 117120087 22 22
385 F 117119887 117119909 117120249 117120271 22 22
407 F 117144095 117144119 117144474 117144501 24 27
373 F 117149029 117149054 117149379 117149401 25 22
389 F 117170876 117170900 117171242 117171264 24 22
400 F 117174096 117174118 117174473 117174495 22 22
405 F 117175170 117175192 117175548 117175574 22 26
398 R 117176788 117176811 117176414 117176436 23 22
400 R 117180444 117180467 117180068 117180091 23 23
368 F 117181977 117181999 117182322 117182344 22 22
399 F 117188572 117188594 117188947 117188970 22 23
393 F 117199428 117199455 117199793 117199820 27 27
400 F 117204633 117204655 117205009 117205032 22 23
407 F 117227727 117227752 117228108 117228133 25 25
391 F 117229276 117229300 117229640 117229666 24 26
391 F 117230316 117230340 117230684 117230706 24 22
350 F 117231911 117231933 117232238 117232260 22 22
381 F 117232152 117232176 117232510 117232532 24 22
352 R 117232738 117232761 117232410 117232433 23 23
395 F 117234787 117234809 117235159 117235181 22 22
385 F 117242814 117242836 117243176 117243198 22 22
359 F 117243536 117243558 117243872 117243894 22 22
407 F 117246609 117246635 117246993 117247015 26 22
375 F 117250507 117250531 117250855 117250881 24 26
367 F 117251413 117251436 117251755 117251779 23 24
362 R 117252038 117252061 117251700 117251722 23 22
391 F 117254606 117254628 117254974 117254996 22 22
386 F 117267447 117267470 117267810 117267832 23 22
373 R 117268068 117268093 117267721 117267743 25 22
353 F 117279805 117279827 117280135 117280157 22 22
397 R 117282697 117282720 117282324 117282348 23 24
376 R 117293111 117293135 117292760 117292783 24 23
377 R 117304966 117304988 117304612 117304634 22 22
355 R 117305675 117305697 117305343 117305368 22 25
376 F 117306889 117306911 117307242 117307264 22 22
400 F 117307518 117307541 117307895 117307917 23 22
397 R 117307585 117307607 117307211 117307233 22 22
372 F 117308082 117308104 117308432 117308453 22 21
373 R 117308142 117308164 117307792 117307814 22 22
393 F 117308381 117308405 117308751 117308773 24 22
Table 1 (continued)
Cystic Fibrosis NGS in Newbornsextracting the following quality-control (QC) metrics for
each sample from the BAM ﬁle: total number of reads,
percentage of reads that were properly paired and mapped
to the reference genome, read depth of each amplicon, and
read depths of individual base pairs within the CFTR ROI
(Supplemental Table S1). At the amplicon level, coverageThe Journal of Molecular Diagnostics - jmd.amjpathol.orguniformity was calculated by obtaining the mean ampli-
con coverage of each sample and then calculating the
percentage of amplicons in that sample that were covered
by at least 20% (0.2  mean) or 50% (0.5  mean) of the
mean amplicon coverage. At the base-pairs level, we
assessed the percentage of bases within the ROI that were271
Lefterova et alcovered at least by 100 reads and the lowest read number
per base pair of each sample. GC content of the CFTR
gene was calculated for each position in the ROI using a
sliding window of 21 bases. Sample coverage was
extracted from pileups generated using pysam (parame-
ters: stepper Z “samtools”; max_depth Z 99,999) on
sample BAM ﬁles.
Variant Calling and Annotation
The clinical laboratory personnel performing the NGS assay
and data analysis were blinded to the expected variants (E.F.
and T.C.). Variant calling was accomplished using two pub-
licly available tools: GATK version 3.3-0-g37228af20,21 and
FreeBayes version v0.9.21-7-g7dd41 db.22 Variant calls using
GATK HaplotypeCaller were made in GVCF mode (parame-
ters genotyping_mode Z DISCOVERY, ERC Z GVCF,
variant_index_typeZ LINEAR, variant_index_parameterZ
128000, maxReadsInRegionPerSample Z 15,000) followed
by joint genotyping using GATK GenotypeGVCFs. Custom-
ized scripts were used for computing actual read depths at
variant positions and for performing variant quality ﬁltering
(QD <2.0 k DP <5 k FS>30 k samtools mpileup read depth
<20 k alt depth/read depth <0.2). FreeBayes was run using
default parameters, and variants were ﬁltered using a
customized script (QUAL <20 k DP <20 k QA/AO <20).
Each variant was further annotated with the corresponding
Human Genome Variation Society DNA and protein-level
nomenclature and dbSNP rs number if available, using
Annovar.23 Variants were also annotated with the corre-
sponding coordinates in the hg19 reference assembly;
legacy name if it existed; and whether the variant fell within
the CFTR ROI (Supplemental Table S1) or was present in
the literature, other public databases, and/or our clinical
laboratoryecurated CFTR database. This laboratory-
curated CFTR database is a comprehensive machine-
readable list of >2000 genomic variants that have been
identiﬁed during clinical CF testing at the Stanford Health
Care Molecular Pathology Laboratory, as well as variants
reported in public databases, including the CF Mutation
Database, the CFTR2 database, National Center for
Biotechnology Information’s dbSNP, and Ensembl (http://
www.ensembl.org).
Variants are designated based on the following reference
sequences: NM_000492.3 (cDNA; http://www.ncbi.nlm.nih.
gov/nuccore/90421312) and NP_000483.3 (protein; http://
www.ncbi.nlm.nih.gov/protein/90421313). Each variant in
this laboratory-curated CFTR database is annotated with
the source of information on the variant (public database
versus internal ﬁnding), whether the variant is considered
clinically reportable or benign, functional annotations and
evolutionary conservation information derived from
Annovar,23 and potential aliases of the variant based on
empirical ﬁndings from automated variant callers. The latter is
particularly relevant for the polymorphic poly-TG and poly-T
tracts and small indels. For example, c.1521_1523delCTT,272p.Phe508del is a deletion of the trinucleotide CTT but is
identiﬁed as a deletion of TCT by the GATK variant caller.
Similarly, each TG-polyT allele is associated with a speciﬁc
GATK and FreeBayes alias (Supplemental Table S2).
TG-polyT genotype calling was performed using a customized
script to look for every possible TG-polyT combination in a
sample, to count the number of reads supporting the call, and
to report the allele frequency (ie, the proportion of reads
supporting a given TG-polyT combination divided by the total
number of reads covering the amplicon). We empirically
found allele frequencies of 0.253 to 0.482 for known hetero-
zygous samples and allele frequencies of 0.58 to 0.722 for
known homozygous samples. Thus, we set the following
allele-frequency thresholds for future applications: 25% to
55% to support a heterozygous call and >55% for a
homozygous call; <25% was considered artefact. All
customized scripts have been deposited to https://github.
com/eulaf/CFseq.
CNV Analysis
Three different methods were applied to analyze CNV:
ExomeDepth,24 CONTRA,25 and log2 coverage ratio plot.
For each data set, we used the mean read coverage of all
of the samples except the one under analysis as “refer-
ence.” In addition, samples with nonuniform read
coverage were excluded from the reference sample set
(speciﬁcally, samples 31 and 33 from the 51-sample set
and samples 12, 48, 60, 92, and 93 from the 96-sample
set; no samples were excluded from the 48-sample set).
For ExomeDepth,24 the analysis was performed by
calculating the reference for each sample individually (eg,
for a 96-sample set, the coverage of all positions for each
sample was calculated 95 times). Alternatively, the anal-
ysis can be easily parallelized by analyzing each sample
on an independent central processing unit core in a
computer server, thus reducing the overall computing
time from roughly 15 hours to <1 hour. For the log2
coverage ratio plot method, the log2 coverage ratio for
each position was calculated according to Li et al.25 The
log2 ratio for each sample was smoothed with LOWESS26
and plotted for each data set, highlighting the exons of
samples with signiﬁcant differences in CNV from other
samples in the same region.
CNV Conﬁrmation by qPCR
We devised a method of quantitative assessment of
CFseq-predicted CNVs by real-time quantitative PCR
(qPCR). The primers used for targeting the predicted
CNVs in exons 2, 3, 4, 5, 25, and 26 and intron 12, as
well as two reference exons (13 and 16), are listed in
Table 1. PCR was performed on a LightCycler 480
(Roche Diagnostics, Indianapolis, IN), using 10-mL re-
actions with 5 mL of 2 LightCycler 480 SYBR Green I
Master mix, 1 or 3 mL of DNA template volume, and 0.1jmd.amjpathol.org - The Journal of Molecular Diagnostics
Cystic Fibrosis NGS in Newbornsto 0.8 mmol/L primer concentration using the following
cycling parameters: 5 minutes at 95C; 50 cycles of 10
seconds at 95C, 10 seconds at 58C, and 20 seconds at
72C; single acquisition at 72C; melting curve analysis
from 60C to 95C, 10 acquisitions per second. We ﬁrst
used genomic DNA to validate the primers and to
establish standard curves for each primer set. Empirical
testing using DBS-derived DNA was used for optimizing
primer concentrations and template amounts for each
primer set. For each sample with a predicted CNV, we
performed qPCR at the exon/intron predicted to be
deleted or ampliﬁed, and normalized the signal to the two
reference exons as follows. Crossing point values were
calculated via standard curves, and CNVs were analyzed
via Relative Quantiﬁcation Analysis built into LC480
software release 1.5.0 SP3. Each target primer set T was
paired with the two reference primer sets R to calculate
the geometric mean of the resulting ratio [eg, T1/R
(all) Z (T1/R1  T1/R2)1/2].
The same analysis was also performed in parallel on two
control specimens (C1 and C2) from the same sample set. The
T1/R (all) ratio of C1 was then used as a normalizer for the
T1/R (all) ratios of C2 and the test sample. If no CNV was
present, the normalized T1/R (all) ratio was expected to be
approximately 1. If a heterozygous deletion was present, the
normalized T1/R (all) ratio was expected to be approximately
0.5, whereas if a duplication was present, the normalized ratio
was expected to be >1.5. In CNVs with normal spot experi-
ments (CNV1 and CNV2), all normal spots were used for
controlling and sampling DNA, so the expected normalized
ratios should all have been close to 1.
Primer Binding-Site Assessment by Sanger Sequencing
To rule out the possibility that a predicted exon/intron deletion
was due to allele dropout, we sequenced the binding regions of
the forward and reverse primers in specimen S6 (intron_12)
from the 48-sample set and in specimens S8 (exon_5) and S23
(exon_4) from the 51-sample set. Only specimens with single
exon deletions were assessed because we reasoned that it was
unlikely for two consecutive exons in the same sample to have
had rare/private variants at primer-binding sites. The following
primers were used for ampliﬁcation and sequencing. To assess
the forward NGS primer for exon_4: CFTR_exon_4-1_F (50-
AGCCTACTCTGATACTGAAAGTTGT-30) and CFTR_
exon_4-1_R (50-GCGTTCCTCCTTGTTATCCGGGT-30);
the reverse NGS primer for exon_4: CFTR_exon_4-2_F
(50-ACCCGGATAACAAGGAGGAACGC-30) and CFTR_
exon_4-2_R (50-AGGCTGTGTGAGTCATCTTAACAGGA-
30); the forward NGS primer for exon_5: CFTR_exon_5-
1_F (50-ACATGAAAAATTCAAGGCCAAGGCT-30) and
CFTR_exon_5-1_R (50-TGTTCAGGTTGTTGGAAAG-
GAGAC-30); the reverse NGS primer for exon_5:
CFTR_exon_5-2_F (50-GCTGTCAAGCCGTGTTCTAGA-
TA-30) and CFTR_exon_5-2_R (50-AAACACATTATCT-
GTCCCAAGGA-30); the forward NGS primer for intron 12:The Journal of Molecular Diagnostics - jmd.amjpathol.orgCFTR_intron_target_17bn-1_F (50-TGGTTTTGCTGTAA-
GGTGCACACA-30) and CFTR_intron_target_17bn-1_R
(50-TCATAACATTTAAATTTTTCAGGTGTGA-30); and
the reverse NGS primer for intron 12: CFTR_intron_
target_17bn-2_F (50-AAGGTTACTATCAATCACACC-
TGA-30) and CFTR_intron_target_17bn-2_R (50-TCC-
TGCCCTTGAAGATGTTGGGT-30). Amplicons were
puriﬁed with the ExoSAP-IT kit (Affymetrix, Santa Clara,
CA). Bidirectional sequencing was performed as previously
described,27 using the BigDye Terminator mix (Life Tech-
nologies) on an ABI 3730 genetic analyzer (Life Technol-
ogies). DNA sequences were analyzed using Mutation
Surveyor software version 4.09 (SoftGenetics, State
College, PA).
Statistical Analysis
All statistical analyses, including determinations of sensitivity,
speciﬁcity, 95% CIs, and linear correlations, were performed
using Prism software (GraphPad Software, La Jolla, CA) and
VassarStats (http://vassarstats.net, last accessed October 21,
2015). Positive predictive value was calculated based on re-
sults from the 48-sample set. Sanger-sequencing results from
the 47 NBS specimens (ie, excluding the nontemplate control)
demonstrated a total of 287 variant positions (ie, true-
positives) and 633,367 nonvariant positions (ie, true-
negatives) within the ROI (13,482 bp).
Results
Assay Design
Current NGS diagnostics are suboptimal for NBS applications
due to their inability to accommodate DBS-derivedmaterial. To
overcome this limitation, we developed an optimized DBS-
processing protocol by systematically evaluating several DBS-
extraction procedures and assessing their performance as NGS
analytes (Supplemental Table S3). The selection of the sodiam
hydroxideebased method as optimal was based on its
adaptability to 96-sample multiplexing, ease of perfor-
mance, reagent cost, total NGS read coverage per sample,
and amplicon coverage uniformity. The ﬁnal protocol is
described in Materials and Methods. Importantly, the
CFseq workﬂow uses only a fraction of the DNA extracted
and eluted from a single 3.2-mm DBS punch spot (4 mL of
approximately 80 mL, with a DNA concentration of
approximately 0.2 ng/mL, ie, approximately 0.8 ng/test)
(Supplemental Table S3), reserving this valuable resource
for other genetic testing.
The selection of CFTR regions to be targeted by the
assay was based on the most comprehensive CF NBS
algorithm currently in clinical use in the United States.8
We chose to use an mPCR strategy for ampliﬁcation of
the approximately 16-Kbp target genomic sequence
because mPCR allows for greater sensitivity, speciﬁcity,
and sequencing uniformity compared with hybrid273
DNA extraction from 
one DBS punch spot per sample
Target capture (mPCR) and
sequencing library preparation
MiSeq sequencing
Demultiplexing (fastq)
Custom QC analysis
(coverage per sample,
amplicon uniformity, 
minimum base coverage)
Variant calling
(vcf files)
CNV analysis
3 hours
7 hours
42 hours
Custom primer trimming
(processed fastq)
0.1 hour
0.15 hour
Alignment to reference
(BAM files)
0.18 hour
0.12 hour 1.8 hours 1-15* hours
Figure 1 Assay workﬂow for comprehensive CFTR sequencing using
blood spots from newborns. Listed are the times for individual steps, when
96 specimens are multiplexed. Computation time for copy number variant
(CNV) analysis can vary based on server cluster speciﬁcations, and therefore
an estimated range is provided based on whether each sample is analyzed
sequentially or in parallel (asterisk). DBS, dried blood spot; mPCR,
multiplex PCR; MiSeq, MiSeq platform (Illumina, San Diego, CA); QC, quality
control.
Lefterova et alcapture methods.28 Additionally, the mPCR approach is
cost-effective as it relies only on oligonucleotide
primers, conventional thermal cyclers, and other
equipment already available in conventional molecular
diagnostic laboratories. The length of capture amplicons
was restricted to approximately 400 bp to accommodate
a 2  250-bp paired-end Illumina MiSeq sequencing
chemistry, to ensure sequence quality and coverage
uniformity by terminal overlap of the forward and
reverse sequencing reads.29
The MiSeq platform was selected because it is a widely used
benchtop NGS instrument that has already been adopted by
many clinical laboratories; however, the workﬂow of CFseq is
expected to accommodate other platforms of similar or higher
capacity. We chose to optimize the procedure for multiplexing
up to 96 samples with consideration of the existing re-
quirements for volume and turnaround time in our laboratory in
performing high-volume genetic screening for CF from DBS.
However, we did not seek to determine the upper limit of
multiplexing capabilities of the assay, which we estimate to be
signiﬁcantly higher based on the achieved depth of sample
coverage.
Finally, NGS data analysis consists of several components,
including sample demultiplexing, alignment to reference
sequence, SNV and small indel variant calling, CNV analysis,
and evaluation of QC metrics (Figure 1). For this assay, we
chose to use primarily publicly available data-analytical tools
that have been widely used and validated and are easily
accessible and deployable in laboratories without dedicated
bioinformaticists. We did, however, incorporate several
customized scripts (see Materials and Methods), and the
performance of each of these assay components.
Quality Assurance and Assay Reliability
To assess assay performance, we implemented a QC al-
gorithm whereby sequencing read coverage was examined
on three different levels: individual samples, sample
amplicons, and sequence bp (Figure 2A). The ﬁrst QC
metric, sample coverage, deﬁned as the number of reads
per sample, was used for detecting samples that completely
failed multiplex ampliﬁcation. In our validation experi-
ments, this approach identiﬁed one sample (S33) with
inadequate coverage (1200 total reads) (Figure 2B). The
second QC metric, amplicon coverage uniformity, was
used for identifying samples with partially failed ampliﬁ-
cation, such as individual amplicons that may have been
insufﬁciently covered despite an overall normal read count
for that sample. This metric is particularly important for
CNV analysis since samples with nonuniform coverage
cannot be analyzed accurately for CNVs. For each sample,
we assessed the number of amplicons that had >0.5-fold
the mean amplicon coverage and used a threshold of 2
SDs below the mean to ﬂag samples for review. This
approach identiﬁed three samples (S48, S60, and S92) with
poor uniformity (Figure 2C). Lastly, we assessed base274coverage for each sample, reasoning that if base coverage
were sufﬁciently high, even samples with low amplicon
uniformity could be analyzed further. As shown in
Figure 2D, three samples ﬂagged in the prior QC steps
(S33, S48, and S60) also had base coverage of<100 reads/
base and were excluded from further analysis and reﬂexed
for repeated DNA extraction and sequencing; sample S92,
in contrast, passed this coverage metric and yielded inter-
pretable results in further analyses. Of the 190 samples that
progressed to analysis, all target bases within the ROI were
covered by at least 100 reads (Figure 2D and Table 2),
providing a high degree of conﬁdence for variant calling.
Importantly, there was no correlation between GC content
and bp coverage, indicating that even difﬁcult-to-sequence
areas of CFTR were appropriately covered (Supplemental
Figure S1). Moreover, the QC performance metrics,
including total number of reads per sample, amplicon
coverage uniformity, and bp coverage, remained robust
whether 48 or 96 samples were processed and tested
simultaneously (Table 2).
Analytical Sensitivity and Speciﬁcity for SNVs and
Small Indels
The 190 DBS samples that passed our QC ﬁlters con-
tained 499 SNV and small indels that we had identiﬁed byjmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 2 Quality-control (QC) algorithm for
read coverage monitoring. A: Read coverage was
examined on three different levels: individual
samples, amplicons, and bp (red). The samples
that failed to pass QC thresholds are indicated. B:
Total reads per sample for all 193 samples that
were sequenced. One sample (S33 from the 51-
sample set) failed to amplify. C: Uniformity of
amplicon coverage. Shown is the percentage of
amplicons with read coverage >0.5-fold the mean
amplicon coverage for each individual sample.
Four samples did not pass the empirically estab-
lished threshold of (mean e 2  SD): S48, S60,
and S92, all from the 96-sample set; in addition to
S33 from the 51-sample set). D: Shown is the
percentage of bp with coverage >100 reads per
bp. Only three samples did not pass this threshold,
indicating that the remaining 190 samples could
be analyzed further. The asterisk indicates a 51-
sample set; dagger, a 96-sample set. DBS, dried
blood spot.
Cystic Fibrosis NGS in NewbornsSanger sequencing and/or mutation panel testing (111
unique positions): 498 within the ROI and 1 well-known
SNV outside the ROI (c.3272-26A>G). The 111 unique
variants comprised 79 substitutions (including missense
and intronic substitutions), 11 nonsense, 7 splice site, and
14 indel (<15 bp long) variants, which included 16 of the
23 mutations recommended by the American College of
Medical Genetics and Genomics and American Congress
of Obstetricians and Gynecologists and 37 of the 39 SNVs
and small indels tested by the State of California
(Supplemental Table S4). Variant calling was compared
between two publicly available tools, GATK20,21 and
FreeBayes.22 FreeBayes detected all expected variants,
whereas GATK failed to call 1 of the 499 variants
(c.-288G>C, which is a variant of uncertain clinical sig-
niﬁcance located in the 50-untranslated region). Thus, to
increase sensitivity, our algorithm uniﬁed all variant calls
from the two tools (GATK and FreeBayes). Indel
realignment and base recalibration were found not to
improve variant calling and in some cases reduced
sensitivity (data not shown).
Relative to the applicable reference method, the analytical
sensitivity of CFseq across the 499 variants was 100% (95%
CI, 99.2% to 100.0%) (Table 3). There were 64 homozygous
calls (allele frequency, >80%), all of which represented
common benign polymorphisms that were concordant with
initial results. The allele frequency of the 435 heterozygous
calls ranged from 38% to 74%; therefore, the reference range
of heterozygosity was deﬁned as 35% to 80%. We also
examined whether the assay detected any unexpected variants
that were not previously reported for the 190 DBSs under
study but that are classiﬁed as reportable in our laboratory-
maintained CFTR variant database. CFseq identiﬁed onlyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthree unexpected variants, and on further analysis, all three
were conﬁrmed by Sanger sequencing: L997F (c.2991G>C,
p.Leu997Phe), I1027T (c.3080T>C, p.Ile1027Thr), and
c.1393-42G>A. These results demonstrate that CFseq is both
highly sensitive and speciﬁc, with a positive predictive value
of 100%. The positive predictive value of the assay was
100% (95% CI, 98.3% to 100%), based on the 48-sample set,
for which NGS results at every ROI position could be
correlated with Sanger sequencing.
Intron 9 TG-PolyT Variant Calling
Intron 9 (legacy name, intron 8; IVS-8) of CFTR contains
a polymorphic region consisting of a tract of 9 to 13 TG
repeats followed by ﬁve to nine consecutive thymidines
(polyT). The 5T allele, which is seen in approximately 5%
of individuals,30 affects the splicing efﬁciency of exon 10
(legacy name, exon 9) in a context-dependent manner.3
When occurring together with 12 or 13 TGs and/or with
other variants such as R117H (c.350G>A, p.Arg117His),
a 5T allele can contribute to the clinical phenotypes
associated with CF and CFTR-related disorders, such as
congenital bilateral absence of the vas deferens.3 As such,
detecting the exact TG-polyT genotype is critically
important to any comprehensive CFTR testing platform;
however, it poses a challenge for NGS alignment algo-
rithms and variant callers due to its repetitive nature.11
Indeed, when default settings of the GATK variant cal-
ler were used, TG-polyT genotypes and allele frequencies
were frequently miscalled. These miscalls necessitated a
customized script for analysis of the region (see Materials
and Methods), whereby the sequencing data from each
sample were queried for all possible TG-polyT275
Table 2 Coverage Metrics and Time Effort for Each Sequence Run
Parameter 48 samples 96 samples 51 samples
Mean reads passed
ﬁlter/sample, n
513,243 237,394 580,340
Mean mapped
reads/sample, %
97.6 97.7 93.0
Mean properly paired
reads/sample, %
89.9 89.6 81.2
Amplicon coverage >0.2
mean, %
97.6 97.0 99.6
Amplicon coverage >0.5
mean, %
85.8 79.3 81.6
Lowest read coverage per
base, n
962 456 1440
Target bases covered
100,* %
100.0 100.0y 100.0y
Time effort, hours/run
Spot punch and DNA
extraction
2.1 3.3 2.1
Target capture and
library preparation
5.8 7 5.8
Sequencing time 42 42 42
Data analysis, QC and
variant calling
2.25 2.25 2.25
CNV analysisz 8 15 8
Total time 60.4 69.8 60.4
*Target bases refers to the 13,482 bp that fall within the region of
interest.
yWhen the three samples that did not pass QC coverage metrics (S33 from
the 51-sample set, S48 and S60 from the 96-sample set) are included,
98.9% (96-sample set) and 98.1% (51-sample set) of target bases are
covered with >100 readsper bp.
zThe CNV analysis computing time is estimated based on calculating the
reference for each sample individually in ExomeDepth.24 This analysis can
also be parallelized by analyzing each sample on an independent central
processing unit core in a computer server, thus reducing the overall
computing time from roughly 15 hours to <1 hour.
CNV, copy number variant; QC, quality control.
Lefterova et alcombinations (Supplemental Table S2) and allele fre-
quencies were calculated for each possible combination.
These computed allele frequencies were used for making
the ﬁnal TG-polyT allele calls based on empirically
established thresholds, which differ from the thresholds
for SNVs (25% to 55% for heterozygous, >55% for ho-
mozygous alleles). Using this approach, CFseq correctly
assigned the TG-polyT genotype to all 169 samples for
which the TG-polyT tract was known, including 27Table 3 Performance Speciﬁcations of the Assay in Clinical Specimen
Speciﬁcation 48
Analytical sensitivity (SNVs and small indels, %; n/N)* 10
Analytical sensitivity (TG-polyT tracts, %; n) 10
Sensitivity in reportable rangey (%) 10
Analytical speciﬁcity (%) 10
*Variants within the region of interest (ROI) called correctly by next-generatio
y% bp within the 13,482-bp ROI that are covered by >100 reads per bp.
polyT, poly-thymidine; SNV, single-nucleotide variant; TG, thymidine-guanine.
276disease-related genotypes (6 samples of 13TG-5T, 10 of
12TG-5T, and 11 of 11TG-5T) (Supplemental Table S5).
CNV Identiﬁcation
Large deletions or insertions in the CFTR gene are estimated
to represent 1% to 2% of all CF-causing mutations31; however,
NBS for CNVs is currently available for only one relatively
common pathogenic variation (ex2,3del), using an oligonu-
cleotide hybridization approach that targets the known break-
points of the variant (Luminex Molecular Diagnostics, Inc.,
Toronto, ON, Canada). Other CNVs in CFTR are typically
detected by multiplex ligation-dependent probe
ampliﬁcation.31e33 NGS platforms have also shown the
ability to detect large exonic deletions or insertions11,34,35;
however, to date, all of these approaches have utilized
high-quality genomic DNA, and their compatibility with
DBS-derived samples has not been assessed. Our sample
set contained only a single known CNV, ex2,3del, which
we were able to detect using a combination of publicly
available tools described in Materials and Methods
(Figure 3A). Interestingly, the CFseq CNV analysis also
detected four other potential deletions and one potential
duplication (Figure 3, A and B). Of these, the exon 25,26
deletion (legacy name: ex22,23del, S16) is of particular
interest as it has been described previously.36
As CNV determination is not a component of the
standard NBS algorithm, these samples had not previ-
ously been assayed for CNVs, and given the inability of
multiplex ligation-dependent probe ampliﬁcation to
assess DBS-derived material, we were unable to verify
these ﬁndings with the current reference method. To in-
crease conﬁdence in the validity of the predicted CNVs,
we analyzed each potential CNV sample with three
distinct CNV detection algorithms, requiring concordance
among all three methods. Four deletions, including the
known ex2,3del, met this requirement (Table 4). Next, we
utilized qPCR to quantitatively assess these CNV pre-
dictions and Sanger sequencing of the primer annealing
regions to identify potential ampliﬁcation failures in these
samples. Of the three single-exon losses, qPCR conﬁrmed
one (S6, intron 12) but did not conﬁrm another (S8, exon
5), whereas Sanger sequencing identiﬁed a rare variant
(c.274-60C>T) under primer 4F as a possible cause of an
ampliﬁcation failure in sample S23, exon 4. qPCRs
samples 96 samples 51 samples
0; 287/287 100; 122/122 100; 89/89
0; 47/47 100; 93/93 100; 29/29
0 100 100
0 100 100
n sequencing method/expected variants.
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S8(exon_5)
S23(exon_4)
S50(exon_2−3)
S42(exon_26)
S6(intron_12)
S16(exon_25−26)
Figure 3 CFTR copy number variant (CNV) detection in dried blood
spot specimens. The results of three computational CNV prediction
methods were integrated and plotted as the log2 ratio of observed versus
expected read counts for each exon of each individual sample. Log2
ratios that signiﬁcantly deviate from baseline are shaded in red if two
consecutive exons show a difference in copy number, and in blue if a
single exon/intron is affected. CNV results for the 51- and 48-sample
sets are shown in A and B, respectively. No signiﬁcant CNVs were
detected in the 96-sample set.
Cystic Fibrosis NGS in Newbornsconﬁrmed the single-exon gain in sample S42, exon 26.
For the two samples with losses of two consecutive exons,
both exons were conﬁrmed for sample S16 and only one
for sample S50 (yes for exon 3, no for exon 2). Notably,
the ex2,3del in S50 was previously detected by Luminex
panel testing (see Study Specimens) and correctly
conﬁrmed by CFseq.
Assay Reproducibility
To assess the reproducibility of CFseq, we ﬁrst evaluated the
consistency of amplicon coverage and found high degrees of
correlation both within individual runs (Supplemental
Figure S2A) and between runs (Supplemental Figure S2B
and C). We also examined the reproducibility of variant
calling within and between runs. For example, c.1521_
1523delCTT, p.Phe508del, the most common pathogenic
CFTR variant, was present in 29 samples in the 48-sample set,
56 samples in the 96-sample set, and 10 samples in the
51-sample set and was correctly identiﬁed in all samples at the
expected heterozygous allele frequencies, indicating 100%
reproducibility for the detection of this pathogenic variant.
Similar results were obtained when comparing other variants
that were present in multiple samples, such as G542X
(c.1624G>T, p.Gly542X).
CFseq Cost and Time-of-Effort Assessments
Current NBS programs are effective in identifying the
majority of newborns who will manifest CF symptoms;
however, the labor, time, and expense of these programs
are considerable due to the algorithmic approach. A
great value of CFseq lies in the ability of the approach to
collapse multiple workﬂows into a single robust pipeline
while reducing cost and effort and streamlining labora-
tory operations. Currently, approximately 9000 new-
borns test positively in the immunoreactive trypsinogenThe Journal of Molecular Diagnostics - jmd.amjpathol.orgscreen in the California State program each year. Current
algorithmic practice8 reﬂexes all of these samples to a
40-mutation panel (roughly 7 hours of hands-on effort
per 39-sample run, typically around 2 days’ turnaround
time), followed by unidirectional Sanger sequencing for
samples in which the panel approach detected only a
single mutation (approximately 5 hours of hands-on time
per 4-sample run and 12 hours’ turnaround time,
required for roughly 560 newborns per year in Califor-
nia). In contrast, CFseq can process 96 samples in
approximately 7 hours of hands-on time with as little as
3 days’ turnaround time (Table 2 and Figure 1). Using
reagent list prices, we estimate that the reagent costs of
CFseq represent approximately a ﬁvefold cost savings
over the conventional tiered NBS scheme, while
providing comprehensive CFTR sequence and copy
number analysis for every sample. We note that these
estimates do not include labor costs or other laboratory
costs, which are highly variable between laboratories and
difﬁcult to estimate. Additionally, the throughput of the
CFseq workﬂow is much greater than those of existing
assays; conventional Sanger sequencing, for example,
can generally accommodate only three or four samples
per run, even with the largest general-use sequencers
available (27 amplicons for full CFTR coverage across
96 capillaries), whereas CFseq can easily accommodate
96 samples in each run, and potentially severalfold more
with further sample multiplexing for even higher
throughput.Discussion
Current NBS strategies for CF are undeniably clinically
useful; however, they have limitations due to their reli-
ance on older molecular technology. We designed and
validated CFseq, a highly sensitive, speciﬁc, rapid, and
potentially cost-effective NGS assay for comprehensive
clinical CFTR analysis from newborn DBSs. CFseq
represents a major advance over currently used CF NBS
techniques because it is the ﬁrst to deliver comprehen-
sive CFTR analysis for this sample typedincluding the
detection of SNVs, indels, and large deletionsdfrom a
single 3.2-mm DBS punch. Moreover, its affordability,
low hands-on time requirements, and ease of imple-
mentation make it generally accessible to clinical mo-
lecular laboratories equipped to perform NGS testing. In a
single assay, CFseq has the potential to effectively replace
all current CF genetic NBS assays (ie, mutation panels and
Sanger sequencing), diagnostic assays (eg, bidirectional
Sanger sequencing), and potentially assays for large de-
letions (eg, multiplex ligation-dependent probe ampliﬁca-
tion), although this latter functionality will require further
validation.
NGS technologies have many advantages in molec-
ular diagnostics, and other groups have already applied277
Table 4 Comparison of CFTR Clinical Sequencing Assays
Study NGS assay CFTR target size Sample type (DNA amount) DBS Sensitivity, %
Abou Tayoun et al12 AmpliSeq custom panel with two
separate PCR primer pools, Ion
torrent sequencing
CDS, 10,343 bp 79 peripheral blood samples and
Coriell cell lines (20 ng)
No 98.6
Trujillano et al11 NimbleGen SeqCap EZ Choice
array, Illumina HiSeq2000
Entire CFTR genomic
locus, 182 Kbp
92 peripheral blood samples of CF
patients and carriers (1.1 mg)
No 100
Grosu et al13 Illumina TruSeq Custom
Amplicon, MiSeqDx Cystic
Fibrosis Clinical Sequencing
Assay
CDS, two deep intronic
variants and two
large deletions
366 peripheral blood samples
and cell lines (250 ng)
No 99.68
Bonini et al37 NimbleGen SeqCap EZ kit, or
long-range PCR, 454 GS Junior
Sequencer
Entire CFTR genomic
locus, 188 Kbp
18 peripheral blood samples
(500 ng)
No
Baker et al15 Illumina TruSeq Custom Amplicon,
MiSeqDx Cystic Fibrosis Clinical
Sequencing Assay
CDS, two deep intronic
variants and two
large deletions
232 DBS samples
(1  3.2 mm DBS punch)
Yes 100
Loukas et al42 Multiplicom MASTR version 2
multiplex PCR, Illumina
MiSeq
CDS, selected intronic
regions and promotor
188 peripheral blood samples
and 12 DBS
Yes
Lefterova et al
(this study)
Lab-developed multiplex
PCR, Illumina MiSeq
CDS, two deep intronic
variants, 16,513 bp
193 DBS samples (1  3.2 mm
punch, w1 ng/sample)
(table continues)
Yes 100
Characteristics of recently developed targeted NGS assays that enable CFTR sequence analysis and detection of common CNVs.
*Illumina MiSeqDX CF clinical sequencing assay was conﬁgured for a maximum of eight samples per run. Both Grosu et al13 and Baker et al15
showed 48-sample multiplexing.
CDS, coding sequence; CF, cystic ﬁbrosis; CNV, copy number variant; DBS, dried blood spot; NA, not available; NBS, newborn screening;
NGS, next-generation sequencing; polyT, poly-thymidine; TAT, turnaround time; TG, thymidine-guanine.
Lefterova et althem to CF diagnosis, with varying degrees of success
(Table 5). However, existing assays are generally
impractical to implement in clinical NBS on a larger
scale, such as the approximately 9000 DBS specimens
processed annually in our laboratory. For example, the
assays developed by Trujillano et al11 and Bonini
et al,37 both of which use commercial hybrid-based
target enrichment of the entire CFTR genomic locus,
enable the detection of rare deep intronic variants;
however, this approach markedly increases sample
sequencing cost and requires DNA quantities that
cannot be obtained from DBS without ampliﬁcation
(eg, whole genome ampliﬁcation), which in turn may
compromise copy-number detection.38 Moreover, the
sequencing platforms used by Abou Tayoun et al12 and
Bonini et al37 are error prone in homopolymer regions,
which can affect base calling in the CFTR polymorphic
TG-polyT tracts. Two recent studies (Grosu et al13 and
Baker et al15) reported the implementation of the
Cystic Fibrosis Clinical Sequencing Assay (Illumina),
which has been conﬁgured by the manufacturer for a
maximum of eight samples per run (Illumina technical
note: MiSeqDx Cystic Fibrosis Clinical Sequencing Assay.
San Diego, CA). Although both studies demonstrated
multiplexing of 48 samples per run, the assay still results in
higher per-sample sequencing costs, cannot easily be
modiﬁed by end-users to include additional CFTR regions278of interest, and can be run only on a dedicated instrument
(MiSeqDx).
CFseq was designed speciﬁcally to address the practical
limitations of existing NGS assays for CF NBS applica-
tions and has four primary advantages. First, CFseq has
very low input requirements of 1 ng and can accommo-
date DBS-derived samples without preampliﬁcation. Sec-
ond, CFseq utilizes standard PCR instrumentation, thus
avoiding more expensive capture technologies and
specialized infrastructure that are typically required for
commercial NGS assays. Third, CFseq enables testing at
both high sample volumes and at very low cost, which are
prerequisites for any assay to be implemented in NBS.
Lastly, current NBS assays do not offer truly comprehen-
sive CFTR analysis capable of detecting both rare
sequence-based changes as well as larger deletions and/or
duplications, whereas CFseq can detect all known CF-
related CFTR variant types. Although the ﬁrst three dif-
ferentiators are largely logistical, the last may result in
direct clinical care consequences. For example, whereas
large deletions compose only 1% to 2% of all disease-
causing CFTR mutations overall,31 large deletions can
account for a much greater proportion of CF chromosomes
in some populations.39,40 The deletion of exons 2 and 3,
ex2,3del, for example, accounts for up to 6% of all CF
chromosomes in individuals of Eastern- and Western-
Slavic descent.41 Routine CF screening tests do notjmd.amjpathol.org - The Journal of Molecular Diagnostics
Speciﬁcity, % Precision, % Reagent cost Effort Limitations in NBS
97 100 $154 and $103 per sample when
12 and 35 samples, respectively,
are pooled per run
NA Homopolymer sequencing errors with
2184delA false-positive calls; poly-TG
and polyT tract not reported
100 91 $200 per sample w14 days’ TAT High DNA sample requirement, and
limited multiplexing of 24 samples
100 99.7 $220 per sample if 48 samples
are pooled (w$1320 per sample
if 8 samples are pooled*)
<3 hours; hands-on time
based on Illumina Data
sheet
High 250 ng DNA sample requirement;
MiSeqDX special instrumentation
NA NA High 500 ng DNA sample requirement,
and high error rate in homopolymeric
polypyrimidine tract base calling
100 w220 per sample if 48 samples are
pooled (w$1320 per sample if
eight samples are pooled*)
w1 week TAT, <3 hours;
hands-on time based
on Illumina data sheet
Investigator-use-only mode limited
to the sequence analysis of 162
CFTR mutations; MiSeqDx special
instrumentation
w$300 per sample when 10
samples
are pooled per run
w1-week TAT Limited multiplexing of up to 20
samples/run; no CNV analysis
provided
100 100 w$15 per sample when 95 samples
are pooled per run
w7 hours; hands-on time,
w3 days’ TAT
Table 4 (continued)
Cystic Fibrosis NGS in Newbornsdetect most CNVs, and the specialized testing modalities
available (eg, multiplex ligation-dependent probe ampli-
ﬁcation) are incompatible with DBS-derived samples.
During its validation, CFseq, in contrast, detected mul-
tiple different deletions, including ex2,3del, ex25,26
(legacy name, ex22,23del), and three other putative
single-exon or single-intron deletions and one putative
single-exon gain. Using a combination of three CNV callers,
normalized qPCR analysis, and Sanger sequencing to rule
out allele dropout, we were able to conﬁrm four of the six
CNVs (Table 4). We found that the largest source of error in
the qPCR analysis was the lack of reliable standard curves
due to insufﬁcient DNA amounts from DBS, which also
limited the range of available DNA concentrations in this
experiment. Other limitations of the method include an
untested lower limit of size detection, laborious differentia-
tion between allele dropout and true deletion (eg, by Sanger
sequencing as in this study), and an unknown true rate of
samples producing nonuniform coverage in routine clinical
testing. Although these ﬁndings for CNV prediction based
on CFseq are encouraging, they also demonstrate that
clinical implementation will require further validation.
Nonetheless, it is tempting to speculate that the wide-
spread application of technologies such as CFseq might
uncover additional CFTR structural variants and expand
our understanding of the true frequency and diversity of
these events.The Journal of Molecular Diagnostics - jmd.amjpathol.orgAlthough CFseq provides comprehensive sequence
analysis of the coding regions of CFTR and several key
regulatory elements, it does not interrogate the entire
intronic sequence of the gene such as the assays by
Trujillano et al11 and Bonini et al.37 This design choice
was made because of both the relative rarity of CF-
associated variants in these regions [only two deeply
intronic pathogenic variants (c.1679þ1.6kbA>G and
c.3717þ12191C>T) have been described to occur with
any appreciable frequency,4 and both are covered by
CFseq], and the relatively high rate of intronic genetic
variation relative to exonic. These two parameters make
full intronic analysis of CF fraught with a high rate of
variants of uncertain signiﬁcance, which may cause
parental anxiety and incur costly and unnecessary
clinical follow-up.7 However, if additional novel, deeply
intronic variants not currently covered by CFseq are
characterized and validated as pathogenic,4 they can be
easily incorporated into the existing assay through the
addition of supplemental ampliﬁcation primer sets.
Even within the CFTR coding sequence, many of the
variants detected in comprehensive molecular assays are
of unclear clinical signiﬁcance. Therefore, although CF
screening identiﬁes newborns at risk for CF, it is typi-
cally followed by diagnostic testing, such as sweat
chloride measurements and evaluation by CF specialist
physicians, to reach a deﬁnitive clinical diagnosis. In that279
Table 5 CNV Detection with CFseq
Data set Sample and region CNV type ExomeDepth24 CONTRA25 Coverage ratio plot qPCR agreement Primer region sequencing
51 samples S8 (exon_5) Loss N Y Y N N
S23 (exon_4)* Loss Y Y Y N c.274-60C>Ty
S42 (exon_26) Gain Y Y N Y NA
S50 (exon_2-3)* Loss Y Y Y Y-e3, N-e2 NA
48 samples S6 (intron_12)* Loss Y Y Y Y N
S16 (exon_25-26)* Loss Y Y Y Y-e25, e26 NA
Analysis using three computational algorithms predicted CNVs in six samples, four of which were concordant among all three methods. qPCR
quantitatively conﬁrmed four of six CNV samples, with the exception of exon 2 in sample S50, which was a known exon 2,3 deletion sample based on
Luminex panel testing. Sanger sequencing of primer annealing regions identiﬁed a rare variant under primer 4F in S23 (primer base position 18,
marked with an underline below) as a possible cause of an allele-speciﬁc ampliﬁcation failure. The CNV in sample 8 that was predicted by only two of
the three methods was not conﬁrmed.
*Predicted CNVs for which all three prediction algorithms agreed.
yLocated 8 bp from the 30 end of primer 4F (50-AGTCTTGTGTTGAAATTCTCAGGGT-30).
CNV, copy number variant; NA, not available; qPCR, real-time quantitative PCR.
Lefterova et alcontext, ongoing efforts to establish genotypeephenotype
correlations are particularly important and can assist in
the interpretation and classiﬁcation of variants as path-
ogenic or benign.4 For example, the CFTR2 database
(http://www.cftr2.org) characterizes the clinical and
functional consequences of individual variants through
clinical follow-up of a large number of CF patients.
Throughout the design and development of CFseq,
every effort was made to facilitate the deployability of
this workﬂow in the clinical molecular diagnostic lab-
oratory. As with all NGS workﬂows, reproducibility
requires duplication of both the technical assay per-
formance and the bioinformatics interpretation. In our
experience, most laboratories ﬁnd the latter more
difﬁcult. As such, we used publicly available, free
bioinformatics tools in our sequence data interpretation
pipeline. Whereas these tools have excellent overall
performance, we did note one speciﬁc weakness in this
application: small indels, although reliably detected,
were occasionally inaccurately named and designated in
the .vcf output. For example, the c.2105-2117del
13insAGAAA variant in our validation was called as two
separate variants: an insertion of an A at chr7:117232191
and a deletion of TTCAATCCT at chr7:117232197.
Similarly, the variants of the clinically relevant and
highly polymorphic TG-polyT tract were called using
nonstandard nomenclature. Despite the fact that the
nomenclature for complex indels returned by these tools
is occasionally inaccurate, variant detection is highly
reliable and calls are reproducible (ie, any given variant
will always be designated the same way). As such, we
were able to implement a customized script in our
analysis pipeline (see Materials and Methods) to match
literature norms by using a simple alias-lookup table
(Supplemental Table S2).
CFseq represents a major advance in CF diagnosis, but
the technology underpinning the assay is fundamentally
agnostic to the speciﬁc analytical target; that is, it may be
easily adapted and applied to other NBS targets such as
BTD (deﬁciencies in which cause biotinidase deﬁciency),280PAH (mutations in which cause phenylketonuria), the
hemoglobin genes (mutations in which cause various
thalassemias and sickle cell disease), and many others (eg,
the State of California currently screens for 80 genetic
diseases). Moreover, given the low input requirements of
CFseq, our optimized DBS sampleeprocessing protocol
yields sufﬁcient material for many assays based on this
technology platform (CFseq may be performed using as
little as 0.8 ng of starting material, whereas our optimized
DBS preparation may yield up to 20 ng per 3.2-mm DBS
punch). Additionally, this approach is further amenable to
the simultaneous interrogation of multiple targets in par-
allel; indeed, a comprehensive NBS panel comprising all
routine genetic screening targets is well within the capa-
bilities of this platform. It should be noted, however, that
certain challenges will need to be addressed before NBS
programs can broadly adopt comprehensive molecular
assays. Those challenges include cost and maintenance of
NGS instrumentation, and the level of technical expertise
required for testing as well as for interpretation and
reporting. Solutions to these challenges may involve either
incorporating NGS-based testing into existing workﬂows,
or outsourcing it to dedicated reference laboratories.
In summary, we describe the development of CFseq, the
ﬁrst truly comprehensive CFTR assay, and describe its
advantages over existing assays in terms of analytical
performance, sample requirements, turnaround time,
hands-on labor, cost, and clinical yield. Moreover, this
assay is speciﬁcally designed to be deployed in clinical
molecular diagnostic laboratories, where it can consolidate
CFTR testing, which now comprises at least two distinct
sample types (DBSs for NBS and peripheral blood for
testing beyond the newborn period) and at least three
different technologies (mutation panel testing, Sanger
sequencing, and multiplex ligation-dependent probe
ampliﬁcation) and their associated workﬂows. Impor-
tantly, this approach can accommodate DBS-derived
samples and has the potential to incorporate multiple tar-
gets in addition to CFTR, for a truly comprehensive NBS
platform.jmd.amjpathol.org - The Journal of Molecular Diagnostics
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